Hayat Pharmaceutical Industries Co. PLC, together with its subsidiary, provides human and veterinary medicines in Jordan. More Details
Excellent balance sheet with proven track record.
Share Price & News
How has Hayat Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HPIC is not significantly more volatile than the rest of JO stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HPIC's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: HPIC exceeded the JO Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: HPIC exceeded the JO Market which returned 36.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Hayat Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Hayat Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: HPIC (JOD3.9) is trading above our estimate of fair value (JOD1.38)
Significantly Below Fair Value: HPIC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: HPIC is good value based on its PE Ratio (9.9x) compared to the Asian Pharmaceuticals industry average (24.7x).
PE vs Market: HPIC is good value based on its PE Ratio (9.9x) compared to the JO market (13.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HPIC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HPIC is good value based on its PB Ratio (1.5x) compared to the XA Pharmaceuticals industry average (2.4x).
How is Hayat Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hayat Pharmaceutical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Hayat Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HPIC has high quality earnings.
Growing Profit Margin: HPIC's current net profit margins (22.2%) are higher than last year (21.4%).
Past Earnings Growth Analysis
Earnings Trend: HPIC's earnings have grown by 10.5% per year over the past 5 years.
Accelerating Growth: HPIC's earnings growth over the past year (12.9%) exceeds its 5-year average (10.5% per year).
Earnings vs Industry: HPIC earnings growth over the past year (12.9%) underperformed the Pharmaceuticals industry 18.3%.
Return on Equity
High ROE: HPIC's Return on Equity (14.6%) is considered low.
How is Hayat Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: HPIC's short term assets (JOD16.9M) exceed its short term liabilities (JOD3.7M).
Long Term Liabilities: HPIC's short term assets (JOD16.9M) exceed its long term liabilities (JOD898.1K).
Debt to Equity History and Analysis
Debt Level: HPIC's debt to equity ratio (8.5%) is considered satisfactory.
Reducing Debt: HPIC's debt to equity ratio has increased from 0.6% to 8.5% over the past 5 years.
Debt Coverage: HPIC's debt is well covered by operating cash flow (112.3%).
Interest Coverage: HPIC's interest payments on its debt are well covered by EBIT (43.3x coverage).
What is Hayat Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HPIC's dividend (2.56%) isn’t notable compared to the bottom 25% of dividend payers in the JO market (3.5%).
High Dividend: HPIC's dividend (2.56%) is low compared to the top 25% of dividend payers in the JO market (6.7%).
Stability and Growth of Payments
Stable Dividend: HPIC is not paying a notable dividend for the JO market, therefore no need to check if payments are stable.
Growing Dividend: HPIC is not paying a notable dividend for the JO market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: HPIC is not paying a notable dividend for the JO market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HPIC's dividend in 3 years as they are not forecast to pay a notable one for the JO market.
How experienced are the management team and are they aligned to shareholders interests?
Maher Mohammed Al Kurdi (43 yo)
Dr. Maher Mohammed Ali Al Kurdi is Founder of Hayat Pharmaceutical Industries Co. PLC and serves its Chairman, General Manager and Executive Director.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hayat Pharmaceutical Industries Co. PLC's company bio, employee growth, exchange listings and data sources
- Name: Hayat Pharmaceutical Industries Co. PLC
- Ticker: HPIC
- Exchange: ASE
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: د.أ37.050m
- Shares outstanding: 9.50m
- Website: https://www.hayatpharma.com
Number of Employees
- Hayat Pharmaceutical Industries Co. PLC
- PO Box 1564
Hayat Pharmaceutical Industries Co. PLC, together with its subsidiary, provides human and veterinary medicines in Jordan. The company offers products in various categories, such as anti-vertigo medication,...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/17 11:32|
|End of Day Share Price||2021/09/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.